triple g retatrutide Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v New weight-loss drug rivaling bariatric

This program is a great fit for adults who are generally healthy and looking to reduce food noise, improve digestion, decrease inflammation, and support their cardiovascular health without the aggressive dosing of a full medical weight loss program

This article breaks down that paradox, explains why discomfort is such a powerful biological signal, and shows how intensity shapes everything from lactate metabolism to brain chemistry to long-term resilience

From oral formulations to wearable devices, these innovations are poised to revolutionize the way patients experience weight loss and wellness treatments

As research into GLP-1 RAs continues, these drugs could become a cornerstone in a comprehensive, multi-faceted approach to managing diabetes complicationshelping patients not only control their blood sugar but also protect their kidneys and heart